AbstractThe biggest hurdle to targeted cancer therapy is the inevitable
emergence of drug resistance. Tumor cells employ different mechanisms to resist
the targeting agent. Most commonly inEGFR-mutant non-small cell lung cancer,
secondary resistance mutations on the target kinase domain emerge to diminish
the binding affinity of first- and second-generation inhibitors. Other
alternative resistance... hiện toàn bộ